We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo.
- Authors
Tao, Yong; Lamas, Veronica; Du, Wan; Zhu, Wenliang; Li, Yiran; Whittaker, Madelynn N.; Zuris, John A.; Thompson, David B.; Rameshbabu, Arun Prabhu; Shu, Yilai; Gao, Xue; Hu, Johnny H.; Pei, Charles; Kong, Wei-Jia; Liu, Xuezhong; Wu, Hao; Kleinstiver, Benjamin P.; Liu, David R.; Chen, Zheng-Yi
- Abstract
Mutations in Atp2b2, an outer hair cell gene, cause dominant hearing loss in humans. Using a mouse model Atp2b2Obl/+, with a dominant hearing loss mutation (Oblivion), we show that liposome-mediated in vivo delivery of CRISPR-Cas9 ribonucleoprotein complexes leads to specific editing of the Obl allele. Large deletions encompassing the Obl locus and indels were identified as the result of editing. In vivo genome editing promotes outer hair cell survival and restores their function, leading to hearing recovery. We further show that in a double-dominant mutant mouse model, in which the Tmc1 Beethoven mutation and the Atp2b2 Oblivion mutation cause digenic genetic hearing loss, Cas9/sgRNA delivery targeting both mutations leads to partial hearing recovery. These findings suggest that liposome-RNP delivery can be used as a strategy to recover hearing with dominant mutations in OHC genes and with digenic mutations in the auditory hair cells, potentially expanding therapeutics of gene editing to treat hearing loss. Liposome-mediated gene editing was used to abolish a mutation in gene Atp2b2 and recover hearing in a mouse model of dominant deafness. Editing was also used to target two mutations to recover hearing. The study detected large deletions due to editing.
- Subjects
HEARING disorders; CRISPRS; HEARING impaired; HAIR cells; GENOME editing; CELL survival
- Publication
Nature Communications, 2023, Vol 14, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-023-40476-7